Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus

To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and non-antithrombotic therapy - for the treatment of VT.

Inclusion Criteria:

• Adults with ventricular thrombus(VT), regardless of sex, basic diseases, occupation or education;
• The VT should be found newly within 3 months;
• The observational phase should last until the time that patients who had achieved thrombus resolution. The following up period after the phase ended should continue for at least 3 months.

Exclusion Criteria:

• Individuals received standard antithrombotic therapy within 4 weeks;
• Individuals received the thrombectomy therapy, ventricular aneurysm resection or heart transplantation within 6 weeks since the VT was found in the first time;
• Had a long history of VT more than three months.